Mepsevii has been approved for use in Europe to treat the ultra-rare disease mucopolysaccharidosis type VII (MPS VII), offering patients an approved treatment for the very first time. MPS VII, also known as Sly Syndrome, is a genetic metabolic lysosomal storage disorder, caused by the deficiency of beta-glucuronidase, an enzyme required for the breakdown of
Sanofi and Regeneron have announced that EU regulators have agreed to review Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma. The French pharmaceutical company is seeking approval for Dupixent as an supplementary maintenance treatment in certain adults and adolescents, aged 12 years old and higher, with inadequately controlled moderate-to-severe asthma. The drug
F2G, a biotech based in Manchester, has announced its lead clinical candidate, the antifungal F901318, has been awarded Orphan drug designation in Europe. The drug is the first of a novel class of systemic antifungal agents called orotomides. It is being developed for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium
